Additional associations with MFI found for thioredoxin and downstream factors of the thioredoxin pathway, including PRDX2, RRM2, HIF1A and VEGF, confirm the importance of the thioredoxin system in breast cancer regardless of its ROS-related or unrelated roles. The gene discussed is PRDX2; the disease is breast carcinoma.